Front Row Advisors’s Amgen AMGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $3.15M | Buy |
8,950
+55
| +0.6% | +$19.6K | 1.07% | 27 |
|
|
2025
Q4 | $2.91M | Sell |
8,895
-119
| -1% | -$37.7K | 0.97% | 27 |
|
|
2025
Q3 | $2.54M | Sell |
9,014
-5
| -0.1% | -$1.45K | 0.85% | 33 |
|
|
2025
Q2 | $2.52M | Sell |
9,019
-1
| -0% | -$283 | 0.88% | 29 |
|
|
2025
Q1 | $2.81M | Sell |
9,020
-247
| -3% | -$72.9K | 1.08% | 24 |
|
|
2024
Q4 | $2.42M | Sell |
9,267
-74
| -0.8% | -$22K | 0.83% | 34 |
|
|
2024
Q3 | $3.01M | Sell |
9,341
-48
| -0.5% | -$15.7K | 1.07% | 26 |
|
|
2024
Q2 | $2.93M | Sell |
9,389
-3
| -0% | -$881 | 1.02% | 25 |
|
|
2024
Q1 | $2.67M | Buy |
9,392
+75
| +0.8% | +$21.9K | 0.99% | 26 |
|
|
2023
Q4 | $2.68M | Sell |
9,317
-125
| -1% | -$34.1K | 1.23% | 26 |
|
|
2023
Q3 | $2.54M | Sell |
9,442
-161
| -2% | -$40.2K | 1.17% | 22 |
|
|
2023
Q2 | $2.13M | Buy |
9,603
+6
| +0.1% | +$1.39K | 0.95% | 28 |
|
|
2023
Q1 | $2.32M | Sell |
9,597
-263
| -3% | -$64.6K | 1.11% | 24 |
|
|
2022
Q4 | $2.59M | Sell |
9,860
-145
| -1% | -$38.9K | 1.34% | 19 |
|
|
2022
Q3 | $2.25M | Buy |
10,005
+20
| +0.2% | +$4.85K | 1.17% | 19 |
|
|
2022
Q2 | $2.43M | Sell |
9,985
-18
| -0.2% | -$4.41K | 1.2% | 20 |
|
|
2022
Q1 | $2.42M | Buy |
10,003
+495
| +5% | +$114K | 0.98% | 28 |
|
|
2021
Q4 | $2.14M | Buy |
9,508
+85
| +0.9% | +$17.9K | 0.8% | 37 |
|
|
2021
Q3 | $2M | Sell |
9,423
-75
| -0.8% | -$17.3K | 0.85% | 37 |
|
|
2021
Q2 | $2.13M | Buy |
9,498
+71
| +0.8% | +$17.5K | 0.87% | 33 |
|
|
2021
Q1 | $2.35M | Buy |
9,427
+160
| +2% | +$38.2K | 1.14% | 23 |
|
|
2020
Q4 | $2.13M | Sell |
9,267
-135
| -1% | -$31.1K | 1.09% | 24 |
|
|
2020
Q3 | $2.11M | Sell |
9,402
-139
| -1% | -$34.4K | 1.12% | 25 |
|
|
2020
Q2 | $2.25M | Sell |
9,541
-96
| -1% | -$21.9K | 1.4% | 14 |
|
|
2020
Q1 | $2.31M | Buy |
9,637
+339
| +4% | +$74K | 1.56% | 8 |
|
|
2019
Q4 | $2.24M | Sell |
9,298
-160
| -2% | -$35.3K | 1.46% | 12 |
|
|
2019
Q3 | $1.83M | Sell |
9,458
-225
| -2% | -$43.2K | 1.3% | 19 |
|
|
2019
Q2 | $1.78M | Sell |
9,683
-84
| -0.9% | -$15K | 1.3% | 17 |
|
|
2019
Q1 | $1.86M | Sell |
9,767
-417
| -4% | -$79.6K | 1.45% | 11 |
|
|
2018
Q4 | $1.98M | Buy |
10,184
+377
| +4% | +$73.5K | 1.73% | 8 |
|
|
2018
Q3 | $1.84K | Buy |
9,807
+66
| +0.7% | +$13K | 1.29% | 12 |
|
|
2018
Q2 | $1.88K | Buy |
9,741
+167
| +2% | +$29.5K | 1.2% | 12 |
|
|
2018
Q1 | $1.63M | Buy |
9,574
+205
| +2% | +$37.6K | 1.14% | 16 |
|
|
2017
Q4 | $1.63M | Buy |
+9,369
| New | +$1.66M | 1.3% | 15 |
|
Other funds holding AMGN
VCM
VPM
Front Row Advisors's AMGN Position: Q1 2026 in Review
Front Row Advisors increased its Amgen (AMGN) stake by 0.62% in Q1 2026, buying an estimated $19.6K and bringing the position to 8,950 shares worth $3.15M. The position accounts for 1.07% of the portfolio, ranked #27.
Front Row Advisors first reported a position in AMGN in Q4 2017 and has held it in 34 quarters since. 3,127 funds tracked by Wall St. Rank hold AMGN as of Q1 2026.
- Front Row Advisors held 8,950 shares of Amgen worth $3.15M as of Q1 2026.
- Front Row Advisors bought 55 Amgen shares in Q1 2026, an estimated $19.6K.
- Amgen made up 1.07% of Front Row Advisors's portfolio in Q1 2026, its #27 holding.
- Front Row Advisors first reported a position in Amgen in Q4 2017 and has held it in 34 quarters since.
- 3,127 funds tracked by Wall St. Rank held Amgen as of Q1 2026.
Based on Front Row Advisors's 13F filing for Q1 2026, filed 19 May 2026.